Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli
This article was originally published in The Tan Sheet
Executive Summary
Chattem has not delivered a counter-punch to GlaxoSmithKline's alli, but the firm sees its Dexatrim supplement as "the only one left standing" to compete in the nonprescription weight-loss product categoryYou may also be interested in...
Petition Requests Pre-Market Approval For Supplement Weight-Loss Claims
Manufacturers would need pre-market approval to make weight-loss claims for supplements if FDA implements a rulemaking recommended by petitioners, including GlaxoSmithKline, the manufacturer of OTC weight-loss drug alli.
Chattem Posts Strong Q1 On Selsun Blue Naturals, ACT, Cortisone
The success of Selsun Blue Naturals is leading a revival of the Selsun dandruff franchise, fueling its strongest performance in six periods, Chattem said during an April 8 first quarter analyst call
Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions
Brands Chattem acquired from Johnson & Johnson and continued growth of its own Gold Bond and Icy Hot drove a 51 percent increase in third-quarter revenues, the firm reported Sept. 27
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: